Study in the Journal of Clinical Pharmacology

December 06, 2006

Chemotherapy and radiation for the treatment of various malignancies often result in damage to mucus membranes. Patients suffer ulcerations, pain and an increase risk of infection. Palifermin (Kepivance) is approved for use to decrease the chances of developing severe mucositis or injury to the cells lining the mouth, as well as shorten the time of severe mucositis in patients with cancer. Up to now, it had not been known whether patients with impaired kidney function required any different dosing.

In a recent study published in the December issue of The Journal of Clinical Pharmacology by SAGE Publications, Dr. B. Gillespie and colleagues from Amgen Inc. in Thousand Oaks, CA, conducted a study that assessed the effects of renal function on the pharmacokinetics, safety and tolerability of palifermin after a single IV injection. The clinical trial consisted of 31 participants with varying degrees of renal function, from normal to end-stage renal disease requiring hemodialysis.

Each participant received a single dose of the drug, palifermin. Noone discontinued the study due to adverse events, although 26 subjects reported at least 1 adverse event, mild to moderate in severity which included fatigue and headaches. One subject, who had insulin-dependent diabetes, experienced a significant abnormal glucose level, however, this was not considered related to the study.

The authors concluded that 'these findings indicate that a subject's level of renal function does not appear to affect palifermin clearance or tolerability. Therefore, dose adjustment of palifermin is not indicated for patients with renal impairment.'
-end-
The article "Effect of Renal Function on the Pharmacokinetics of Palifermin" can be accessed at no-charge for a limited time at The Journal of Clinical Pharmacology's web site at www.jclinpharm.org/cgi/reprint/46/12/1460.

About The Journal of Clinical Pharmacology (JCP)
For over 45 years, clinical pharmacologists, clinical and pharmaceutical researchers, drug development specialists, physicians, nurses, and other medical professionals have relied on The Journal of Clinical Pharmacology for original research, special reviews, commentaries, and case reports on all phases of drug development. One of the most highly cited journals in the field, it features up to-the-minute and pertinent clinical information about the safety, tolerability, efficacy, therapeutic applications, toxicology, and total evaluation of new and established drugs for humans. JCP is the official journal for the American College of Clinical Pharmacology. www.jclinpharm.org

About SAGE
SAGE Publications is a leading international publisher of journals, books, and electronic media for academic, educational, and professional markets. Since 1965, SAGE has helped inform and educate a global community of scholars, practitioners, researchers, and students spanning a wide range of subject areas including business, humanities, social sciences, and science, technology and medicine. A privately owned corporation, SAGE has principal offices in Los Angeles, London, New Delhi, and Singapore. www.sagepublications.com

SAGE

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.